CR20240023A - Compuestos de sulfonimidamida y usos de los mismos - Google Patents
Compuestos de sulfonimidamida y usos de los mismosInfo
- Publication number
- CR20240023A CR20240023A CR20240023A CR20240023A CR20240023A CR 20240023 A CR20240023 A CR 20240023A CR 20240023 A CR20240023 A CR 20240023A CR 20240023 A CR20240023 A CR 20240023A CR 20240023 A CR20240023 A CR 20240023A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compounds
- sulfonimidamde
- tautomers
- solvates
- pharmaceutically acceptable
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 abstract 1
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En el presente documento se describen compuestos de sulfonimidamida, solvatos de los mismos, tautómeros de los mismos y sales farmacéuticamente aceptables de los anteriores. Además, en el presente documento se describen procedimientos para tratar un trastorno en un sujeto que necesite de los mismos usando dichos compuestos, solvatos, tautómeros, o sales farmacéuticamente aceptables de los mismos, tales como trastornos mediados por NLRP3.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021107085 | 2021-07-19 | ||
| CN2022077518 | 2022-02-23 | ||
| PCT/US2022/073756 WO2023004257A1 (en) | 2021-07-19 | 2022-07-15 | Sulfonimidamde compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20240023A true CR20240023A (es) | 2024-02-13 |
Family
ID=82899213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20240023A CR20240023A (es) | 2021-07-19 | 2022-07-15 | Compuestos de sulfonimidamida y usos de los mismos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240336625A1 (es) |
| EP (1) | EP4373826A1 (es) |
| JP (1) | JP2024528656A (es) |
| KR (1) | KR20240037240A (es) |
| CN (1) | CN117677622A (es) |
| AR (1) | AR126474A1 (es) |
| AU (1) | AU2022314729A1 (es) |
| CA (1) | CA3222454A1 (es) |
| CL (1) | CL2024000125A1 (es) |
| CO (1) | CO2024001004A2 (es) |
| CR (1) | CR20240023A (es) |
| IL (1) | IL308461A (es) |
| MX (1) | MX2024000634A (es) |
| PE (1) | PE20240246A1 (es) |
| TW (1) | TW202321262A (es) |
| WO (1) | WO2023004257A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| CN119100956B (zh) * | 2024-09-03 | 2025-12-02 | 大连理工大学 | 一种无催化剂的光驱动合成亚磺酰胺类化合物的方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021001044A2 (pt) * | 2018-07-20 | 2021-04-13 | F. Hoffmann-La Roche Ag | Compostos de sulfonimidamida como inibidores da atividade de interleucina-1 |
| JP7843705B2 (ja) * | 2020-01-22 | 2026-04-10 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｎｌｒｐ３モジュレーターとしてのスルホンイミドアミド化合物 |
-
2022
- 2022-07-15 CR CR20240023A patent/CR20240023A/es unknown
- 2022-07-15 EP EP22754730.4A patent/EP4373826A1/en active Pending
- 2022-07-15 US US18/580,607 patent/US20240336625A1/en active Pending
- 2022-07-15 JP JP2024503360A patent/JP2024528656A/ja active Pending
- 2022-07-15 PE PE2024000084A patent/PE20240246A1/es unknown
- 2022-07-15 AU AU2022314729A patent/AU2022314729A1/en active Pending
- 2022-07-15 TW TW111126588A patent/TW202321262A/zh unknown
- 2022-07-15 CA CA3222454A patent/CA3222454A1/en active Pending
- 2022-07-15 WO PCT/US2022/073756 patent/WO2023004257A1/en not_active Ceased
- 2022-07-15 KR KR1020247002067A patent/KR20240037240A/ko active Pending
- 2022-07-15 AR ARP220101872A patent/AR126474A1/es not_active Application Discontinuation
- 2022-07-15 CN CN202280050498.5A patent/CN117677622A/zh active Pending
- 2022-07-15 IL IL308461A patent/IL308461A/en unknown
- 2022-07-15 MX MX2024000634A patent/MX2024000634A/es unknown
-
2024
- 2024-01-15 CL CL2024000125A patent/CL2024000125A1/es unknown
- 2024-01-30 CO CONC2024/0001004A patent/CO2024001004A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR126474A1 (es) | 2023-10-11 |
| WO2023004257A1 (en) | 2023-01-26 |
| IL308461A (en) | 2024-01-01 |
| CN117677622A (zh) | 2024-03-08 |
| MX2024000634A (es) | 2024-02-13 |
| JP2024528656A (ja) | 2024-07-30 |
| PE20240246A1 (es) | 2024-02-19 |
| AU2022314729A1 (en) | 2023-11-30 |
| CL2024000125A1 (es) | 2024-08-23 |
| KR20240037240A (ko) | 2024-03-21 |
| EP4373826A1 (en) | 2024-05-29 |
| TW202321262A (zh) | 2023-06-01 |
| CA3222454A1 (en) | 2023-01-26 |
| CO2024001004A2 (es) | 2024-02-26 |
| US20240336625A1 (en) | 2024-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021006011A (es) | Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma. | |
| JOP20210268B1 (ar) | عوامل تعديل منظِّم توصيل عبر الغشاء في التليف الكيسي | |
| ZA202204929B (en) | Rimegepant for cgrp related disorders | |
| MX2021005700A (es) | Inhibidores de kras g12c y metodos de uso de los mismos. | |
| EP4403175A3 (en) | Inhibitors of kras g12c and methods of using the same | |
| MX2020012731A (es) | Inhibidores de kras g12c y metodos para su uso. | |
| MX2020010836A (es) | Inhibidores de kras g12c y métodos para su uso. | |
| MX2020011582A (es) | Inhibidores de kras g12c y metodos para su uso. | |
| ZA202207667B (en) | Sulfonimidamide compounds as nlrp3 modulators | |
| PH12021550296A1 (en) | Substituted indoles and methods of use thereof | |
| MX2022009366A (es) | Compuestos y usos de estos. | |
| MY199382A (en) | Methods of treating circadian rhythm sleep disorders | |
| TN2019000110A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| MX2021011488A (es) | Compuestos y usos de estos. | |
| WO2019209962A8 (en) | Compounds and uses thereof | |
| CR20240296A (es) | Inhibidores parp1 | |
| MX2020009942A (es) | Compuestos y usos de los mismos. | |
| WO2019209948A8 (en) | Compounds and uses thereof | |
| MX2019008124A (es) | Metodos para el tratamiento de trastornos neurologicos. | |
| EP4249071A3 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| MX2020013352A (es) | Tratamiento para migrañas. | |
| MX2020012980A (es) | Composiciones y métodos para incrementar la exposición plasmática de tetrahidrobiopterina. | |
| MX2022007285A (es) | Compuestos, polimeros, dispositivos y usos de los mismos. | |
| MX2020008678A (es) | Metodos de uso para derivados de benzotriazol trisustituidos. | |
| MX2024000634A (es) | Compuestos de sulfonimidamida y usos de los mismos. |